A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML
LM Kats, SJ Vervoort, R Cole, AJ Rogers, GP Gregory, E Vidacs, J Li, R Nagaraja, KE Yen, RW Johnstone
LEUKEMIA | NATURE PUBLISHING GROUP | Published : 2017
This work was funded by project and program grants (RWJ and LMK) from the National Health and Medical Research Council of Australia (NHMRC) and a grant from the Peter Mac Foundation (LMK). RWJ was supported by an NHMRC Fellowship and LMK was supported by a Victorian Cancer Agency fellowship.